Equities

Heron Therapeutics Inc

Heron Therapeutics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)2.06
  • Today's Change0.04 / 1.98%
  • Shares traded6.72m
  • 1 Year change+82.30%
  • Beta1.8038
Data delayed at least 15 minutes, as of Sep 20 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments8085158
Total Receivables, Net605235
Total Inventory425548
Prepaid expenses6.121413
Other current assets, total------
Total current assets189205254
Property, plant & equipment, net263034
Goodwill, net------
Intangibles, net------
Long term investments------
Note receivable - long term------
Other long term assets8.131618
Total assets223251306
LIABILITIES
Accounts payable3.243.233.80
Accrued expenses757867
Notes payable/short-term debt000
Current portion long-term debt/capital leases------
Other current liabilities, total0.971.000.63
Total current liabilities808271
Total long term debt149149149
Total debt149149149
Deferred income tax------
Minority interest------
Other liabilities, total275.748.00
Total liabilities256237228
SHAREHOLDERS EQUITY
Common stock1.501.191.02
Additional paid-in capital1,8711,8081,690
Retained earnings (accumulated deficit)(1906)(1795)(1613)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total0.01(0.02)(0.01)
Total equity(34)1478
Total liabilities & shareholders' equity223251306
Total common shares outstanding150119102
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.